Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This is a phase II, single arm, open-label, multicenter study to evaluate the efficacy and
safety of Surufatinib single agent or Surufatinib combined with Toripalimab in patients with
advanced solid tumors.